Plasma trimethylamine-N-oxide and related metabolites are associated with type 2 diabetes risk in the Prevención con Dieta Mediterránea (PREDIMED) trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Plasma trimethylamine-N-oxide and related metabolites are associated with type 2 diabetes risk in the Prevención con Dieta Mediterránea (PREDIMED) trial. / Papandreou, Christopher; Bulló, Mònica; Zheng, Yan; Ruiz-Canela, Miguel; Yu, Edward; Guasch-Ferré, Marta; Toledo, Estefanía; Clish, Clary; Corella, Dolores; Estruch, Ramon; Ros, Emilio; Fitó, Montserrat; Arós, Fernando; Fiol, Miquel; Lapetra, José; Serra-Majem, Lluís; Gómez-Gracia, Enrique; Liang, Liming; Fragkiadakis, Georgios A.; Razquin, Cristina; Hu, Frank B.; Salas-Salvadó, Jordi.
In: American Journal of Clinical Nutrition, Vol. 108, No. 1, 2018, p. 163-173.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plasma trimethylamine-N-oxide and related metabolites are associated with type 2 diabetes risk in the Prevención con Dieta Mediterránea (PREDIMED) trial
AU - Papandreou, Christopher
AU - Bulló, Mònica
AU - Zheng, Yan
AU - Ruiz-Canela, Miguel
AU - Yu, Edward
AU - Guasch-Ferré, Marta
AU - Toledo, Estefanía
AU - Clish, Clary
AU - Corella, Dolores
AU - Estruch, Ramon
AU - Ros, Emilio
AU - Fitó, Montserrat
AU - Arós, Fernando
AU - Fiol, Miquel
AU - Lapetra, José
AU - Serra-Majem, Lluís
AU - Gómez-Gracia, Enrique
AU - Liang, Liming
AU - Fragkiadakis, Georgios A.
AU - Razquin, Cristina
AU - Hu, Frank B.
AU - Salas-Salvadó, Jordi
N1 - Publisher Copyright: © 2018 American Society for Nutrition.
PY - 2018
Y1 - 2018
N2 - Background The role of trimethylamine-N-oxide (TMAO) in type 2 diabetes (T2D) is currently partially understood and controversial. Objective The aim of this study was to investigate associations between TMAO and related metabolites with T2D risk in subjects at high risk of cardiovascular disease. Design This is a case-cohort design study within the Prevención con Dieta Mediterránea (PREDIMED) study, with 251 incident T2D cases and a random sample of 694 participants (641 noncases and 53 overlapping cases) without T2D at baseline (median follow-up: 3.8 y). We used liquid chromatography-tandem mass spectrometry to measure plasma TMAO, l-carnitine, betaine, lyso-phosphatidylcholine (LPC) and lyso-phosphatidylethanolamine (LPE) species, phosphocholine, α-glycerophosphocholine, and choline at baseline and after 1 y. We examined associations with the use of weighted Cox proportional hazard models, accounting for the weighted case-cohort design by the Barlow method. Results After adjustment for recognized T2D risk factors and multiple testing, individuals in the highest quartile of baseline TMAO and α-glycerophosphocholine had a lower risk of T2D [HR (95% CI): 0.52 (0.29, 0.89) and 0.46 (0.24, 0.89), respectively]. The HR (95% CI) comparing the extreme quartiles of betaine was 0.41 (0.23, 0.74). Similar trends were observed for C16:0 LPC, C18:1 LPC, C18:0 LPC, C20:4 LPC, C22:6 LPC, C18:1 LPC plasmalogen, and C16:0 LPE. After correcting for multiple comparisons, participants in the highest quartile of 1-y changes in oleic acid LPC plasmalogen concentrations had a lower T2D risk than the reference quartile. Conclusion Whether the associations between plasma TMAO and certain metabolite concentrations with T2D risk reflect its pathophysiology or represent an epiphenomenon needs to be elucidated. This trial is registered at http://www.controlled-trials.com as ISRCTN35739639.
AB - Background The role of trimethylamine-N-oxide (TMAO) in type 2 diabetes (T2D) is currently partially understood and controversial. Objective The aim of this study was to investigate associations between TMAO and related metabolites with T2D risk in subjects at high risk of cardiovascular disease. Design This is a case-cohort design study within the Prevención con Dieta Mediterránea (PREDIMED) study, with 251 incident T2D cases and a random sample of 694 participants (641 noncases and 53 overlapping cases) without T2D at baseline (median follow-up: 3.8 y). We used liquid chromatography-tandem mass spectrometry to measure plasma TMAO, l-carnitine, betaine, lyso-phosphatidylcholine (LPC) and lyso-phosphatidylethanolamine (LPE) species, phosphocholine, α-glycerophosphocholine, and choline at baseline and after 1 y. We examined associations with the use of weighted Cox proportional hazard models, accounting for the weighted case-cohort design by the Barlow method. Results After adjustment for recognized T2D risk factors and multiple testing, individuals in the highest quartile of baseline TMAO and α-glycerophosphocholine had a lower risk of T2D [HR (95% CI): 0.52 (0.29, 0.89) and 0.46 (0.24, 0.89), respectively]. The HR (95% CI) comparing the extreme quartiles of betaine was 0.41 (0.23, 0.74). Similar trends were observed for C16:0 LPC, C18:1 LPC, C18:0 LPC, C20:4 LPC, C22:6 LPC, C18:1 LPC plasmalogen, and C16:0 LPE. After correcting for multiple comparisons, participants in the highest quartile of 1-y changes in oleic acid LPC plasmalogen concentrations had a lower T2D risk than the reference quartile. Conclusion Whether the associations between plasma TMAO and certain metabolite concentrations with T2D risk reflect its pathophysiology or represent an epiphenomenon needs to be elucidated. This trial is registered at http://www.controlled-trials.com as ISRCTN35739639.
KW - case-cohort
KW - Mediterranean diet
KW - metabolites
KW - PREDIMED
KW - trimethylamine-N-oxide
KW - type 2 diabetes
U2 - 10.1093/ajcn/nqy058
DO - 10.1093/ajcn/nqy058
M3 - Journal article
C2 - 29982310
AN - SCOPUS:85050810414
VL - 108
SP - 163
EP - 173
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
SN - 0002-9165
IS - 1
ER -
ID: 358091239